
Ayman A Hussein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10550468/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Off-Label Use and Inappropriate Dosing of Direct Oral Anticoagulants in Cardio-pulmonary Disease. Chest, 2022, , .	0.4	3
2	Increasing Lesion Dimensions of Bipolar Ablation by Modulating the Surface Area of the Return Electrode. JACC: Clinical Electrophysiology, 2022, 8, 498-510.	1.3	4
3	Efficacy and Safety of Catheter Ablation vs Antiarrhythmic Drugs as Initial Therapy for Management of Symptomatic Paroxysmal Atrial Fibrillation: A Meta-Analysis. Reviews in Cardiovascular Medicine, 2022, 23, 112.	0.5	9
4	Outcomes of atrial fibrillation ablation in patients with or without silent pulmonary veins from prior ablation procedure. Journal of Cardiovascular Electrophysiology, 2022, 33, 1994-2000.	0.8	2
5	Radiofrequency ablation using a needle electrode combined with heated saline injection: Three different mechanisms of tissue heating. Heart Rhythm, 2021, 18, 453-454.	0.3	0
6	Comparative Analysis of Procedural Outcomes and Complications Between De Novo and Upgraded Cardiac Resynchronization Therapy. JACC: Clinical Electrophysiology, 2021, 7, 62-72.	1.3	6
7	Device-Related Thrombus After Left Atrial Appendage Occlusion. Journal of the American College of Cardiology, 2021, 78, 314-316.	1.2	3
8	Super and Nonresponders to Catheter Ablation for Atrial Fibrillation: A Quality-of-Life Assessment Using Patient Reported Outcomes. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009938.	2.1	6
9	Cardiac resynchronisation therapy in anthracycline-induced cardiomyopathy. Heart, 2021, , heartjnl-2020-318333.	1.2	3
10	Not Safe at Any Velocity. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009409.	2.1	1
11	Impact of High-Power Short-Duration Radiofrequency Ablation on Esophageal Temperature Dynamic. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e010205.	2.1	4
12	Periprocedural and Shortâ€Term Outcomes of Percutaneous Left Atrial Appendage Closure According to Type of Atrial Fibrillation. Journal of the American Heart Association, 2021, 10, e022124.	1.6	1
13	Bayesian Network Metaâ€Analysis Comparing Cryoablation, Radiofrequency Ablation, and Antiâ€arrhythmic Drugs as Initial Therapies for Atrial Fibrillation Journal of Cardiovascular Electrophysiology, 2021, , .	0.8	3
14	Left atrial appendage closure device implantation in patients at very high risk for stroke. Heart Rhythm, 2020, 17, 27-32.	0.3	9
15	The gap between what patients know and desire to learn about their cardiac implantable electronic devices. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 118-122.	0.5	8
16	Cryoablation for persistent atrial fibrillation: less may be more… sometimes!. Europace, 2020, 22, 333-334.	0.7	1
17	Outcomes of Pulmonary Vein Isolation inÂAthletes. JACC: Clinical Electrophysiology, 2020, 6, 1265-1274.	1.3	8
18	Ablation of Atrial Fibrillation Without Left Atrial Appendage Imaging in Patients Treated With Direct Oral Anticoagulants. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008301.	2.1	12

Ayman A Hussein

#	Article	IF	CITATIONS
19	Rationale, considerations, and goals for atrial fibrillation centers of excellence: A Heart Rhythm Society perspective. Heart Rhythm, 2020, 17, 1804-1832.	0.3	38
20	Impact of riskâ€factor modification on arrhythmia recurrence among morbidly obese patients undergoing atrial fibrillation ablation. Journal of Cardiovascular Electrophysiology, 2020, 31, 1979-1986.	0.8	11
21	Transvenous lead extraction in patients with prior extraction procedures: Procedural profiles and outcomes. Heart Rhythm, 2020, 17, 1904-1908.	0.3	2
22	Clinical Outcomes and Characteristics With Dofetilide in Atrial Fibrillation Patients Considered for Implantable Cardioverter-Defibrillator. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008168.	2.1	3
23	Predictors of longâ€ŧerm outcomes greater than 10 years after cardiac resynchronization therapy implantation. Journal of Cardiovascular Electrophysiology, 2020, 31, 1182-1186.	0.8	6
24	Impact of Bariatric Surgery on Atrial Fibrillation Type. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007626.	2.1	30
25	Catheter Ablation in Patients With Cardiogenic Shock and Refractory Ventricular Tachycardia. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007669.	2.1	13
26	Cardiac venous injuries: Procedural profiles and outcomes during left ventricular lead placement for cardiac resynchronization therapy. Heart Rhythm, 2020, 17, 1298-1303.	0.3	10
27	Transvenous Lead Extraction in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy. JACC: Clinical Electrophysiology, 2019, 5, 665-670.	1.3	3
28	Atrial Tachyarrhythmias Among Patients With Left Ventricular Assist Devices. JACC: Clinical Electrophysiology, 2019, 5, 459-466.	1.3	13
29	Life-Threatening Complications ofÂAtrialÂFibrillation Ablation. JACC: Clinical Electrophysiology, 2019, 5, 284-291.	1.3	25
30	Cardiac Implantable Electronic Device Therapy in Heart Failure. Circulation Research, 2019, 124, 1584-1597.	2.0	37
31	New Model of Automated Patient-Reported Outcomes Applied in Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e006986.	2.1	22
32	Year in Review in Cardiac Electrophysiology. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007142.	2.1	2
33	Lead Location as Assessed on CardiacÂComputed Tomography andÂDifficulty ofÂPercutaneous Transvenous Extraction. JACC: Clinical Electrophysiology, 2019, 5, 1432-1438.	1.3	18
34	Left atrial appendage closure device implantation in patients with prior intracranial hemorrhage. Heart Rhythm, 2019, 16, 663-668.	0.3	18
35	Burden and consequences of retained cardiovascular implantable electronic device lead fragments after heart transplantation. American Journal of Transplantation, 2018, 18, 3021-3028.	2.6	5
36	Recurrent Atrial Fibrillation After Initial Long-Term Ablation Success. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e005785.	2.1	53

AYMAN A HUSSEIN

#	Article	lF	CITATIONS
37	Repeat ablation or medical management alone for recurrent arrhythmias after ablation of persistent atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2018, 29, 551-558.	0.8	14
38	Unrecognized venous injuries after cardiac implantable electronic device transvenous lead extraction. Heart Rhythm, 2018, 15, 318-325.	0.3	15
39	Transvenous Lead Extraction in Chronic Kidney Disease and Dialysis Patients With Infected Cardiac Devices. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e005706.	2.1	17
40	Medical and Interventional Outcomes in Pediatric Lone Atrial Fibrillation. JACC: Clinical Electrophysiology, 2018, 4, 638-648.	1.3	8
41	Smartwatch Algorithm for AutomatedÂDetection of Atrial Fibrillation. Journal of the American College of Cardiology, 2018, 71, 2381-2388.	1.2	334
42	Outcomes and Management of Patients With Severe Pulmonary Vein Stenosis From Prior Atrial Fibrillation Ablation. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006001.	2.1	21
43	RemovalÂof subcutaneous defibrillator shocking coils: Lessons to learn for future extraction of subcutaneous defibrillator systems. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 1341-1344.	0.5	6
44	Ablation of atrial fibrillation: Facts for the referring physician. Cleveland Clinic Journal of Medicine, 2018, 85, 789-799.	0.6	1
45	Incidence, indications, risk factors, and survival of patients undergoing cardiac implantable electronic device implantation after open heart surgery. Europace, 2017, 19, euw234.	0.7	21
46	Persistent Atrial Fibrillation Ablation With or Without Contact Force Sensing. Journal of Cardiovascular Electrophysiology, 2017, 28, 483-488.	0.8	27
47	Atrial Fibrillation and Pulmonary Venous ElectricalÂConduction Recovery AfterÂFullÂSurgicalÂResection and AnastomosisÂofÂthe Pulmonary Veins. JACC: Clinical Electrophysiology, 2017, 3, 559-567.	1.3	5
48	Transvenous lead extraction at the time of cardiac implantable electronic device upgrade: Complexity, safety, and outcomes. Heart Rhythm, 2017, 14, 1807-1811.	0.3	26
49	2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. Heart Rhythm, 2017, 14, e503-e551.	0.3	792
50	Initial Experience With Non-Vitamin K Antagonist Oral Anticoagulants for Short-Term Anticoagulation After Left Atrial Appendage ClosureÂDevice. JACC: Clinical Electrophysiology, 2017, 3, 1472-1473.	1.3	8
51	Lead Extraction Considerations for the Referring Cardiologist. Cardiology in Review, 2017, 25, 17-21.	0.6	2
52	Cardiac Implantable Electronic DeviceÂInfections. JACC: Clinical Electrophysiology, 2017, 3, 1-9.	1.3	54
53	Microbiology of Cardiac Implantable Electronic Device Infections. JACC: Clinical Electrophysiology, 2016, 2, 498-505.	1.3	79
54	Initial Experience With High-Risk Patients Excluded From Clinical Trials. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	2.1	10

AYMAN A HUSSEIN

#	Article	IF	CITATIONS
55	Radiofrequency Ablation of Persistent Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2016, 9, e003669.	2.1	65
56	Safety of Catheter Ablation for AtrialÂFibrillation in Patients With PriorÂCerebrovascular Events. JACC: Clinical Electrophysiology, 2016, 2, 162-169.	1.3	9
57	Extracción de electrodos transvenosos de dispositivos electrónicos implantables cardiacos: ¿quién, cuándo, cómo y dónde?. Revista Espanola De Cardiologia, 2016, 69, 3-6.	0.6	13
58	Transvenous Lead Extraction of Cardiac Implantable Electronic Devices: Who, When, How and Where?. Revista Espanola De Cardiologia (English Ed), 2016, 69, 3-6.	0.4	3
59	Radiofrequency Ablation with an Enhancedâ€Irrigation Flexibleâ€Tip Catheter versus a Standardâ€Irrigation Rigidâ€Tip Catheter. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 1151-1158.	0.5	7
60	Serial measures of cardiac troponin T levels by a highly sensitive assay and incident atrial fibrillation in a prospective cohort of ambulatory older adults. Heart Rhythm, 2015, 12, 879-885.	0.3	32
61	Nomogram for predicting 30-day all-cause mortality after transvenous pacemaker and defibrillator lead extraction. Heart Rhythm, 2015, 12, 2381-2386.	0.3	50
62	Safety of Computed Tomography in Patients With Cardiac Rhythm Management Devices. Journal of the American College of Cardiology, 2014, 63, 1769-1775.	1.2	30
63	Characteristics, treatment, and outcomes of periprocedural cerebrovascular accidents during electrophysiologic procedures. Journal of Interventional Cardiac Electrophysiology, 2013, 37, 41-46.	0.6	2
64	Cardiomyocyte Injury Assessed by a Highly Sensitive Troponin Assay and Sudden Cardiac Death in the Community. Journal of the American College of Cardiology, 2013, 62, 2112-2120.	1.2	39
65	Spontaneous Dissociated Firing from the Pulmonary Veins during Ablation of Paroxysmal Atrial Fibrillation: Implications and Impact on Arrhythmiaâ€Free Survival. PACE - Pacing and Clinical Electrophysiology, 2013, 36, 988-993.	0.5	4
66	Peripheral Arterial Disease and Progression of Coronary Atherosclerosis. Journal of the American College of Cardiology, 2011, 57, 1220-1225.	1.2	84
67	Radiofrequency Ablation of Atrial Fibrillation in Patients With Mechanical Mitral Valve Prostheses. Journal of the American College of Cardiology, 2011, 58, 596-602.	1.2	30
68	Natural History and Long-Term Outcomes of Ablated Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2011, 4, 271-278.	2.1	144
69	Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia. Therapeutics and Clinical Risk Management, 2010, 6, 183.	0.9	7
70	Initial experience with the Evolution mechanical dilator sheath for lead extraction: Safety and efficacy. Heart Rhythm, 2010, 7, 870-873.	0.3	67
71	Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: A safe and efficacious periprocedural anticoagulation strategy. Heart Rhythm, 2009, 6, 1425-1429.	0.3	151